Bioxytran Inc
Bioxytran, Inc., a clinical stage pharmaceutical company, focuses on the development, manufacture, and commercialization of therapeutic drugs to address hypoxia in humans. The company's lead drug candidate is BXT-25, an oxygen-carrying small molecule consisting of bovine hemoglobin stabilized with a co-polymer for use in the treatment of hypoxic conditions in the brain resulting from stroke, and … Read more
Bioxytran Inc (BIXT) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: 0.014x
Based on the latest financial reports, Bioxytran Inc (BIXT) has a cash flow conversion efficiency ratio of 0.014x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-41.47K) by net assets ($-2.90 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Bioxytran Inc - Cash Flow Conversion Efficiency Trend (2016–2024)
This chart illustrates how Bioxytran Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Bioxytran Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Bioxytran Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Orange Minerals NL
AU:OMX
|
-0.049x |
|
GAMING FAC. SA B ZY 01
F:9JU
|
N/A |
|
Tiga Gaming Inc.
TWO:6536
|
-0.070x |
|
Agripower France Sa
PA:ALAGP
|
-0.394x |
|
Aeva Technologies, Inc. Warrants
NYSE:AEVAW
|
-0.973x |
|
Golden Land Bhd
KLSE:7382
|
-0.063x |
|
BTM Resources Bhd
KLSE:7188
|
-0.033x |
|
SINTEZA S.A.
RO:STZ
|
N/A |
Annual Cash Flow Conversion Efficiency for Bioxytran Inc (2016–2024)
The table below shows the annual cash flow conversion efficiency of Bioxytran Inc from 2016 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $-1.79 Million | $-55.74K | 0.031x | -87.54% |
| 2023-12-31 | $-3.10 Million | $-775.38K | 0.250x | -54.35% |
| 2022-12-31 | $-3.30 Million | $-1.80 Million | 0.547x | +1.79% |
| 2021-12-31 | $-3.16 Million | $-1.70 Million | 0.537x | -5.06% |
| 2020-12-31 | $-1.94 Million | $-1.10 Million | 0.566x | +4.98% |
| 2019-12-31 | $-799.29K | $-431.03K | 0.539x | -34.64% |
| 2018-12-31 | $-225.31K | $-185.90K | 0.825x | +101609.04% |
| 2017-12-31 | $542.39K | $440.00 | 0.001x | -99.44% |
| 2016-12-31 | $-290.60K | $-42.39K | 0.146x | -- |